-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Sees Large Drop in Short Interest
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Sees Large Drop in Short Interest
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN – Get Rating) was the target of a large decline in short interest during the month of November. As of November 30th, there was short interest totalling 19,900 shares, a decline of 20.1% from the November 15th total of 24,900 shares. Based on an average daily volume of 20,400 shares, the short-interest ratio is currently 1.0 days. Approximately 0.1% of the company's stock are sold short.
Eledon Pharmaceuticals Price Performance
Shares of Eledon Pharmaceuticals stock traded up $0.08 during trading on Friday, hitting $2.49. 19,788 shares of the stock were exchanged, compared to its average volume of 48,222. The stock has a market cap of $34.25 million, a price-to-earnings ratio of -0.94 and a beta of 1.83. The firm's 50-day moving average price is $2.48 and its 200 day moving average price is $2.88. Eledon Pharmaceuticals has a 12-month low of $2.27 and a 12-month high of $5.14.
Get Eledon Pharmaceuticals alerts:Eledon Pharmaceuticals (NASDAQ:ELDN – Get Rating) last announced its quarterly earnings results on Monday, November 14th. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.05). As a group, research analysts forecast that Eledon Pharmaceuticals will post -2.61 earnings per share for the current year.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its stake in Eledon Pharmaceuticals by 1.4% in the first quarter. Vanguard Group Inc. now owns 679,243 shares of the company's stock valued at $2,676,000 after purchasing an additional 9,543 shares during the period. CM Management LLC increased its stake in Eledon Pharmaceuticals by 8.9% in the third quarter. CM Management LLC now owns 245,000 shares of the company's stock valued at $676,000 after purchasing an additional 20,000 shares during the period. Ensign Peak Advisors Inc increased its stake in Eledon Pharmaceuticals by 13.2% in the third quarter. Ensign Peak Advisors Inc now owns 87,286 shares of the company's stock valued at $241,000 after purchasing an additional 10,186 shares during the period. State Street Corp increased its stake in Eledon Pharmaceuticals by 10.5% in the first quarter. State Street Corp now owns 44,692 shares of the company's stock valued at $176,000 after purchasing an additional 4,257 shares during the period. Finally, Renaissance Technologies LLC increased its stake in shares of Eledon Pharmaceuticals by 74.2% during the second quarter. Renaissance Technologies LLC now owns 32,173 shares of the company's stock worth $79,000 after acquiring an additional 13,700 shares during the period. 47.53% of the stock is currently owned by institutional investors and hedge funds.About Eledon Pharmaceuticals
(Get Rating)
Eledon Pharmaceuticals, Inc, clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes.
See Also
- Get a free copy of the StockNews.com research report on Eledon Pharmaceuticals (ELDN)
- MarketBeat: Week in Review 12/12 – 12/16
- Which Two Bluechip Tech Companies Have Raised Their Guidance?
- Should You Worry About Elon Musk Selling His Tesla Shares?
- Can Tractor Supply Stock Surge Past Cup-With-Handle Buy Point?
- This is no Time to Buy Lennar but the Time is Coming
Receive News & Ratings for Eledon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eledon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN – Get Rating) was the target of a large decline in short interest during the month of November. As of November 30th, there was short interest totalling 19,900 shares, a decline of 20.1% from the November 15th total of 24,900 shares. Based on an average daily volume of 20,400 shares, the short-interest ratio is currently 1.0 days. Approximately 0.1% of the company's stock are sold short.
艾尔顿制药公司(纳斯达克代码：ELDN-GET评级)是空头股数11月份大幅下跌的目标。截至11月30日，空头股数共有19,900股，较11月15日的24,900股减少20.1%。以日均成交量20,400股计算，目前短息比为1.0天。该公司约0.1%的股票被卖空。
Eledon Pharmaceuticals Price Performance
Eledon制药公司的价格表现
Shares of Eledon Pharmaceuticals stock traded up $0.08 during trading on Friday, hitting $2.49. 19,788 shares of the stock were exchanged, compared to its average volume of 48,222. The stock has a market cap of $34.25 million, a price-to-earnings ratio of -0.94 and a beta of 1.83. The firm's 50-day moving average price is $2.48 and its 200 day moving average price is $2.88. Eledon Pharmaceuticals has a 12-month low of $2.27 and a 12-month high of $5.14.
在周五的交易中，Eledon PharmPharmticals的股价上涨了0.08美元，达到2.49美元。该股成交量为19,788股，而平均成交量为48,222股。该股市值为3425万美元，市盈率为-0.94倍，贝塔系数为1.83。该公司的50日移动均线价格为2.48美元，200日移动均线价格为2.88美元。Eledon PharmPharmticals的12个月低点为2.27美元，12个月高位为5.14美元。
Eledon Pharmaceuticals (NASDAQ:ELDN – Get Rating) last announced its quarterly earnings results on Monday, November 14th. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.05). As a group, research analysts forecast that Eledon Pharmaceuticals will post -2.61 earnings per share for the current year.
纳斯达克(ELDN-GET Rating)上一次公布季度收益是在11月14日(星期一)。该公司公布本季度每股收益(0.73美元)，低于普遍预期的(0.68美元)(0.05美元)。研究分析师预测，作为一个整体，Eledon PharmPharmticals本年度的每股收益将为2.61美元。
Institutional Inflows and Outflows
机构资金流入和流出
About Eledon Pharmaceuticals
关于Eledon制药公司
(Get Rating)
(获取评级)
Eledon Pharmaceuticals, Inc, clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes.
Eledon PharmPharmticals，Inc.是一家临床阶段的生物制药公司，专注于为患有自身免疫性疾病和肌萎缩侧索硬化症(ALS)并需要器官或细胞移植的患者开发药物。它的主要候选产品包括AT-1501，一种人源化的针对CD40配体的单抗，是一种表达在人类免疫系统T细胞表面的分子，目前正处于治疗ALS的2a期临床试验，以及胰岛细胞移植治疗1型糖尿病的2期临床试验。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Eledon Pharmaceuticals (ELDN)
- MarketBeat: Week in Review 12/12 – 12/16
- Which Two Bluechip Tech Companies Have Raised Their Guidance?
- Should You Worry About Elon Musk Selling His Tesla Shares?
- Can Tractor Supply Stock Surge Past Cup-With-Handle Buy Point?
- This is no Time to Buy Lennar but the Time is Coming
- 免费获取StockNews.com关于Eledon制药的研究报告(ELDN)
- MarketBeat：回顾一周12/12-12/16
- 哪两家蓝筹科技公司提高了他们的指引？
- 你应该担心埃隆·马斯克出售他持有的特斯拉股票吗？
- 拖拉机库存能否突破杯柄收购点？
- 现在不是购买Lennar的时候，但时机即将到来
Receive News & Ratings for Eledon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eledon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Eledon PharmPharmticals Daily》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Eledon PharmPharmticals和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧